Abstract
Background Antimicrobial Resistance (AMR) is a major global health threat but its burden has not been extensively described in Uganda. We aimed to investigate the antibiotic resistance related mortality, length of hospital stays (LOS) and Disability Adjusted Life Years (DALYs).
Methods This was a retrospective study of clinical records of patients with infectious syndromes admitted at Arua, Jinja and Mbale regional referral hospitals between October 2022 and September 2023. Data was abstracted from clinical records and analyzed to derive the mortality, LOS, DALYs, and factors associated with AMR and mortality using the modified Poisson regression model.
Results Of the 291 participants included in the analysis, 56.6% were males, 10% were living with HIV, and their median age was 35 years (IQR: 21-56). The most common infectious syndromes were sepsis (43.6%) and diarrhea (9.6%). The prevalence of antibiotic-resistant infections (ARI) was 29.6%, while that for multi-drug resistant infections (MDRI) was 17.9%. Patients at Jinja and Mbale RRHs exhibited a 2.42 and 2.65 higher risk of ARI respectively compared to those at Arua RRH. Overall, mortality due to an infectious syndrome was 44.7%, of which 34.9% was due to ARI while 30.8% of the ARI related mortality was due to MDR infections. Most deaths were due to sepsis (42.3%), followed by pneumonia (15.4%) and meningitis (6.2%). Participants with comorbidities had higher risk of mortality due to ARI (45% vs. 31% for those without comorbidities). Among Gram-negative bacteria, Escherichia coli and Klebsiella spp contributed most to mortality, while among Gram-positives, Staphylococcus aureus and Enterobacter spp contributed equally. Patients with ARI’s LOS was 1.2 times higher than that for those without ARI while a longer LOS was associated with a 21% higher ARI risk but a 24% decline in risk of death. ARI was associated with higher DALYs, 235.4, compared to 147.0 for non-ARI.
Conclusion The study revealed a high burden of AMR in Uganda, including a high prevalence of MDR and associated mortality, particularly among patients with comorbidities. This indicates an urgent need for stewardship and infection prevention strategies to control the AMR burden.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by the Royal Society of Tropical Medicine and Hygiene (RSTMH) Early Career Award in partnership with the National Institute for Health and Care Research (NIHR).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Makerere University School of Biomedical Sciences Institutional Review Boards (SBS-2023-329), which granted a waiver of consent to use the clinical records of patients with infectious syndromes at the participating hospitals. The study was also approved by the Uganda National Council of Science and Technology (HS3088ES).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Data Availability
All data will be availed after acceptance
